Cargando…
Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease
Cardiovascular diseases (CVDs) comprise 45% of all deaths in Europe and causes 3.9 million deaths annually. Coronary artery disease (CAD) which includes myocardial infarction (MI) represents the most common form of CVD. A relevant proportion of MI cases seems preventable since reports claim that up...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022893/ https://www.ncbi.nlm.nih.gov/pubmed/31940748 http://dx.doi.org/10.3390/biom10010125 |
_version_ | 1783498122859642880 |
---|---|
author | Shrivastava, Apurva Marzolla, Vincenzo Weidmann, Henri Caprio, Massimiliano Tregouet, David-Alexandre Zeller, Tanja Karakas, Mahir |
author_facet | Shrivastava, Apurva Marzolla, Vincenzo Weidmann, Henri Caprio, Massimiliano Tregouet, David-Alexandre Zeller, Tanja Karakas, Mahir |
author_sort | Shrivastava, Apurva |
collection | PubMed |
description | Cardiovascular diseases (CVDs) comprise 45% of all deaths in Europe and causes 3.9 million deaths annually. Coronary artery disease (CAD) which includes myocardial infarction (MI) represents the most common form of CVD. A relevant proportion of MI cases seems preventable since reports claim that up to two-thirds of these patients exhibit symptoms suggestive for MI within 12 months prior to the acute MI event. An early identification of these at-risk subjects is necessary to manage an early and efficient treatment during the ischemic phase. The aim of the PRecision MEDicine in Coronary Artery Disease (PREMED-CAD) consortium is to apply a system medicine approach towards studying and identifying an ischemia specific ‘biomarker signature’ that improves the identification of individuals ‘at-risk’ for acute MI. The consortium will take an interdisciplinary and translational approach integrating knowledge from CAD epidemiology, imaging, bioinformatics, statistics and molecular biology, as well as existing phenotypic, blood-based and clinical biomarker data of distinct CAD and subclinical MI phenotypes. This biomarker signature will be validated through atherosclerosis-prone mouse models and human cohorts. The validated signature will be translated in a real-world clinical setting using an ongoing clinical trial comprising patients with subclinical ischemia. The aim of the knowledge obtained from this project is to aid in early MI detection and reduce the mortality and morbidity rate in these at-risk MI individuals. |
format | Online Article Text |
id | pubmed-7022893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70228932020-03-12 Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease Shrivastava, Apurva Marzolla, Vincenzo Weidmann, Henri Caprio, Massimiliano Tregouet, David-Alexandre Zeller, Tanja Karakas, Mahir Biomolecules Concept Paper Cardiovascular diseases (CVDs) comprise 45% of all deaths in Europe and causes 3.9 million deaths annually. Coronary artery disease (CAD) which includes myocardial infarction (MI) represents the most common form of CVD. A relevant proportion of MI cases seems preventable since reports claim that up to two-thirds of these patients exhibit symptoms suggestive for MI within 12 months prior to the acute MI event. An early identification of these at-risk subjects is necessary to manage an early and efficient treatment during the ischemic phase. The aim of the PRecision MEDicine in Coronary Artery Disease (PREMED-CAD) consortium is to apply a system medicine approach towards studying and identifying an ischemia specific ‘biomarker signature’ that improves the identification of individuals ‘at-risk’ for acute MI. The consortium will take an interdisciplinary and translational approach integrating knowledge from CAD epidemiology, imaging, bioinformatics, statistics and molecular biology, as well as existing phenotypic, blood-based and clinical biomarker data of distinct CAD and subclinical MI phenotypes. This biomarker signature will be validated through atherosclerosis-prone mouse models and human cohorts. The validated signature will be translated in a real-world clinical setting using an ongoing clinical trial comprising patients with subclinical ischemia. The aim of the knowledge obtained from this project is to aid in early MI detection and reduce the mortality and morbidity rate in these at-risk MI individuals. MDPI 2020-01-11 /pmc/articles/PMC7022893/ /pubmed/31940748 http://dx.doi.org/10.3390/biom10010125 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Concept Paper Shrivastava, Apurva Marzolla, Vincenzo Weidmann, Henri Caprio, Massimiliano Tregouet, David-Alexandre Zeller, Tanja Karakas, Mahir Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease |
title | Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease |
title_full | Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease |
title_fullStr | Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease |
title_full_unstemmed | Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease |
title_short | Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease |
title_sort | design and rationale of the era-cvd consortium premed-cad—precision medicine in coronary artery disease |
topic | Concept Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022893/ https://www.ncbi.nlm.nih.gov/pubmed/31940748 http://dx.doi.org/10.3390/biom10010125 |
work_keys_str_mv | AT shrivastavaapurva designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease AT marzollavincenzo designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease AT weidmannhenri designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease AT capriomassimiliano designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease AT tregouetdavidalexandre designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease AT zellertanja designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease AT karakasmahir designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease |